Department of Experimental and Clinical Medicine, Institute of Dermatology, University of Udine, Udine, Italy,
BioDrugs. 2015 Apr;29(2):91-101. doi: 10.1007/s40259-015-0119-4.
Erythrodermic psoriasis (EP) is a severe form of psoriasis that may be associated with serious and sometimes fatal complications. The treatment of EP is often a challenge, since several factors, including treatment failure or possible complications, may limit favorable outcomes with traditional drugs. Recent evidence suggests that biological drugs, including both anti-tumor necrosis factor alpha agents and ustekinumab, may be useful in improving the management of EP. Unfortunately, since subjects with EP are usually excluded from pivotal trials involving biological agents, this evidence is currently dispersed in small case series and single case reports. In this paper, we briefly analyze conventional therapies for EP, before going on to critically evaluate the existing clinical evidence for the role of current biological drugs, namely infliximab, etanercept, adalimumab, and ustekinumab. Finally, we discuss the potential benefits that newer/developmental biological agents could bring to the management of EP.
红皮病型银屑病（EP）是一种严重的银屑病形式，可能与严重且有时危及生命的并发症有关。EP 的治疗通常是一个挑战，因为包括治疗失败或可能的并发症在内的多种因素可能会限制传统药物的良好效果。最近的证据表明，生物药物，包括抗肿瘤坏死因子-α 制剂和乌司奴单抗，可能有助于改善 EP 的治疗。不幸的是，由于 EP 患者通常被排除在涉及生物制剂的关键试验之外，因此目前这方面的证据分散在小病例系列和单个病例报告中。在本文中，我们简要分析了 EP 的常规治疗方法，然后批判性地评估了目前生物药物（即英夫利昔单抗、依那西普、阿达木单抗和乌司奴单抗）的现有临床证据。最后，我们讨论了新型/研发中的生物制剂可能为 EP 治疗带来的潜在益处。
